Note: Descriptions are shown in the official language in which they were submitted.
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
HIGH PRESSURE SPRAY-DRY OF BIOACTIVE MATERIALS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to and benefit of a prior U.S.
Provisional
Application number 60/434,377, "High Pressure Spray-Dry of Bioactive
Materials", by Vu
Truong-Le, et al., filed December 17, 2002. The full disclosure of the prior
application is
incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The invention is in the field of spray-dry particle formation and
preservation
of bioactive materials. The present invention provides, e.g., viscosity
enhancers to allow
high pressure spraying of sensitive molecules without shear stress
degradation. High
pressure spraying allows fine spray droplets to be dried, e.g., in a shorter
time, at a lower
temperature, with less concomitant degradation of sensitive molecules. High
pressure
spraying produces powder particles wherein the incorporated bioactive material
can be more
readily reconstituted at higher concentrations. The present invention provides
methods and
systems to precisely control spray droplet size and powder particle size by
adjustment of
process variables.
BACKGROUND OF THE INVENTION
[0003] Methods to preserve biologic materials in storage have a long history,
from
the preservation of food to the preservation of modern pharmaceutical
compositions.
Biological materials have been dried, salted, frozen, cryoprotected, spray
dried, and freeze-
dried. Optimal methods of preservation can depend on the acceptable degree of
degradation, the desired storage time, and the nature of the biological
material.
[0004] For centuries, food has been preserved for later consumption by drying.
Food harvested in times of plenty was laid out in the sun to remove excess
water. Drying
can make the food unsuitable for growth of spoilage bacteria and fungi.
Autolytic
processes, in which plant and animal tissues self destruct, can also be
prevented by drying.
Salting food can provide a similar preservative effect. Dried and salted food
usually
-1-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
experiences a loss of fresh appearance and nutritional value. Drying and
salting bioactive
materials, such as enzymes and pharmaceuticals, destroy activity by heat,
oxidation, water
removal, production of radicals and peroxides, photobleaching, and the like,
that denature
the material.
[0005] Spray drying has been used in food processing and pharmaceutical
production with some advantages over salting or slow drying. Water can be
quickly
removed by spraying a fine mist of the dissolved biological molecules into a
stream of hot
gasses. The dried particles can have a large surface to volume ratio for
speedy
reconstitution with aqueous buffers. In Platz et al., U.S. Patent number
6,165,463,
"Dispersible Antibody Compositions and Methods for Their Preparation and Use",
for
example, dry powder particles are prepared by spray drying for inhaled
administration of
pharmaceuticals to patients. The biological molecules, in a dilute solution,
are sprayed at
moderate pressures (e.g., 80 psi) into a stream of hot gasses (e.g., 98-
105°C) for primary
drying, then the particles are further dehydrated by prolonged exposure to
high temperatures
(e.g., 67°C). Although such processes are suitable for food and rugged
biomolecules,
sensitive molecules can be denatured, or otherwise inactivated, by the stress,
long drying
periods, and high temperatures of these methods.
[0006] Freezing can be an effective way to preserve biological molecules. Cold
temperatures can slow degradation reaction kinetics. Freezing can reduce the
availability of
water to degradation reactions and contaminant microbes. Ice can reduce
oxidation of the
molecules by blocking contact with air. However, freezing can have negative
effects such
as concentration of salts that can denature proteins in the unfrozen solution,
or the formation
of sharp ice crystals that can pierce cell structures. Some of the damage
caused by freezing
can be mitigated by the addition of cryoprotectants which prevent denaturation
by lowering
the freezing temperature and inhibiting formation of ice crystals. Even in
cases where
freezing and thawing degradation can be avoided, continuous operation of
refrigeration
equipment can make preservation by storage in a freezer inconvenient and
expensive.
[0007] Freeze-drying processes have many of the benefits of freezing and
drying.
Degradation is suspended by freezing then water removal makes the product more
stable for
storage. Drying by sublimation of the frozen water into a vacuum can avoid the
high heat
-2-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
of some spray drying processes. The lyophilized product can be quite stable in
storage even
at room temperatures. However, the molecules can still experience denaturing
salt
concentrations during the freezing step. In addition, many freeze-drying
protocols call for
prolonged secondary drying steps at high temperatures to reduce moisture
content. Bulky
cakes of lyophilized material can be slow to reconstitute and must be finely
ground for
delivery by inhalation.
[0008] A need remains for compositions and methods to prepare stable particles
containing bioactive materials without loss of purity due to excessive heat,
chemical, or
shear stress. The present invention provides these and other features that
will become
apparent upon review of the following.
SUMMARY OF THE INVENTION
[0009] The present invention provides, e.g., methods to prepare stable
compositions
of bioactive materials with low process denaturation. Methods of preparing
powder
particles, e.g., by spray drying viscous solutions at high pressures reduce
shear stress and
heat stress degradation. The invention provides adjustments in process
parameters to
precisely tune the size of sprayed droplets and dried powder particles.
Stability and shelf
life are increased for the powder particles which can be reconstituted to high
concentrations
without undue aggregation.
[0010] The methods of preparing stable particles include preparing an aqueous
suspension or solution with a bioactive material and a viscosity enhancing
agent, spraying
the suspension or solution through a nozzle at high pressure to form a mist of
fine droplets,
drying the droplets to form powder particles, and recovering the particles.
The viscosity
enhancing agent can be present in a concentration, e.g., sufficient to provide
a 5% or more
viscosity increase, or a 0.05 centipoise or more viscosity increase, over the
suspension or
solution without viscosity enhancing agent.
[0011] The bioactive materials of the method can include peptides,
polypeptides,
proteins, viruses, bacteria, antibodies, cells, liposomes, and/or the like.
For example, the
bioactive material can be a monoclonal antibody present in the process
suspension or
solution at a concentration ranging from about 1 mg/ml to about 200 mg/ml,
from about 5
-3-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
mg/ml to about 80 mg/ml, or about 50 mg/ml. Optionally, the bioactive material
can be,
e.g., a virus present in the suspension or solution in a titer ranging from
about 2 log FFU/ml
to 12 log FFU/ml, or about 8 log FFU/ml.
[0012] The viscosity enhancing agents can be, e.g., a polyol and/or a polymer.
For
example, the polyol can be trehalose, sucrose, sorbose, melezitose, glycerol,
fructose,
mannose, maltose, lactose, arabinose, xylose, ribose, rhamnose, palactose,
glucose,
mannitol, xylitol, erythritol, threitol, sorbitol, raffinose, and/or the like.
Exemplary polymer
viscosity enhancing agents can include starch, starch derivatives,
carboxymethyl starch,
hydroxyethyl starch (HES), dextran, dextrin, polyvinyl pyrrolidone (PVP),
human serum
albumin (HSA), inulin, gelatin, and/or the like. The viscosity enhancing
agents of the
invention can be present in the suspension or solution, e.g., an amount
ranging from about
0.1 weight percent to about 20 weight percent, 2 weight percent to 8 weight
percent, or 6
weight percent. Optionally, the viscosity enhancing agent can be present in a
concentration,
e.g., sufficient to provide a 50%, or a 0.05 centipoise increase in viscosity,
or more.
[0013] The solution or suspension of the method can include a surfactant
and/or a
zwitterion. Surfactants in the method can include, e.g., polyethylene glycol
sorbitan
monolaurates (e.g., Tween 80), polyoxyethylenesorbitan monooleates (e.g.,
Tween 20), or
block polymers of polyethylene and polypropylene glycol (e.g., Pluronic F68),
and/or the
like. Zwitterions of the method can include, e.g., arginine, histidine,
glycine, and/or the
like. The average size of sprayed droplets can be adjusted by varying the
concentration of
surface active agents in the suspension or solution, e.g., preferably in the
presence of
sucrose.
[0014] High pressure spraying through nozzles in the method can include, e.g.,
high
pressure spraying of liquid, atomization with a high pressure gas, and/or
spraying into a
cold fluid. Spraying can be by high pressure nitrogen gas atomization. The
nozzle can have
an internal diameter ranging, e.g., from about 50 ~m to about 500 Vim, from
about 75 ~m to
about 150 Vim, or the nozzle orifice can have an internal diameter of about
100 Vim. The
high pressure spraying nozzle can be an atomizing nozzle with channels for a
high pressure
atomizing gas, e.g., to enhance dispersal of the sprayed droplets. The high
pressure
-4-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
atomizing gas, such as nitrogen, can have a pressure or temperature at least
10% away from
a critical point for the gas.
[0015] The method of the invention can include, e.g., spray freeze-drying the
suspension and/or solution droplets. The fine droplets can be, e.g., immersed
in a cold fluid
to freeze the droplets. The cold fluid can be , e.g., gaseous or liquid argon,
helium, carbon
dioxide, and/or nitrogen. The cold fluid can range in temperature, e.g., from
about
-80°C to about -200°C. The droplets can be dried, e.g., by
applying a vacuum and raising
the temperature of the environment around the droplets to form powder
particles. The
vacuum can be a gas pressure less than about 200 Torr.
[0016] Solutions or suspensions can be sprayed at high pressure to create a
fine mist
of droplets. The high pressure can be, e.g., between about 200 psi and about
2500 psi,
between about 1000 psi and 1500 psi, or about 1300 psi. The fine mist can
include droplets
with an average diameter between about 2 ~m and about 200 ~,m, between about 3
~.m and
about 70 pm, between about 5 ~m and about 30 ~,m, or about 10 Vim.
[0017] Droplets can be dried to form powder particles, e.g., by displacement
of the
gas from the fine mist with a drying gas to remove water vapor and other spray
gasses. The
drying gas can be, e.g., a substantially inert gas, such as nitrogen at a
temperature between
about 25°C and about 99°C, about 35°C and about
65°C, or about 55°C. The powder
particles of the invention can have an average size ranging from about 0.1 ~m
to about 100
Vim, or from about 2 ~m to about 10 ~.m.
[0018] The method of the invention can provide a high process yield without
significant reduction in product purity. For example, the method can have a
process yield
ranging from about 40 percent to about 98 percent, or about 90 percent. The
product purity
of a protein bioactive material can be less than about 5 percent, 4 percent 3
percent, 2
percent, or less total aggregates and fragments on reconstitution of the
powder particles.
The product purity of a protein or viability of a virus bioactive material can
be substantially
the same before and after the drying of droplets.
[0019] Powder particles can be used, e.g., to administer the bioactive
material
according to the methods of the invention. The powder particles can be
delivered to a
-5-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
mammal by inhalation through the nasal and/or pulmonary route. Alternately,
the powder
particles can be reconstituted with an aqueous buffer for delivery of the
bioactive material
by injection. Powder particles of the method can be reconstituted into a
suspension or
solution of bioactive material at a concentration ranging, e.g., from about 1
mg/ml to about
400 mg/ml, or 5 mg/ml to about 200 mg/ml. Substantially isotonic (an
osmolality within
about 10% of physiological values) reconstituted material can comprise
antibodies at a
concentration of about 200 mg/ml.
[0020] Compositions of the invention are, e.g., stable powder particles
readily
reconstituted to solutions of highly pure bioactive materials at high
concentrations.
Compositions of the invention can be, e.g., pa~~ticles containing a bioactive
material made
by the process of preparing an aqueous suspension or solution with the
bioactive material
and a viscosity enhancing agent, spraying the suspension or solution through a
nozzle at
high pressure to form a mist of fine droplets, drying the droplets to form
powder particles,
and recovering the particles. The viscosity enhancing agent can be present at
a
concentration adequate to provide a 5°Io or more increase in viscosity,
or a 0.5 centipoise
increase in viscosity, over the suspension of solution without the viscosity
enhancing
agents.
[0021] The bioactive materials can be peptides, polypeptides, proteins,
viruses,
bacteria, antibodies, cells, liposomes and/or the like. Bioactive materials
can be present in
the process suspension or solution at a concentration ranging, e.g., from
about 1 mg/ml to
about 200 mg/ml, about 5 mg/ml to about 80 mg/ml, or about 50 mg/ml. Viral
bioactive
materials, such as influenza virus, can be present in suspensions or solutions
at a titer
ranging from about 2 log FFU/ml to about 12 log FFU/ml, or about 8 log FFU/ml.
In the
powder particle product, the bioactive material can be present, e.g., in the
powder particles
in an amount ranging from about 0.1 weight percent to about 80 weight percent.
[0022] In one example embodiment, the bioactive material of the composition
can
be, e.g., an antibody, such as a monoclonal antibody, present in the process
suspension or
solution in an amount ranging from about 0.5 weight percent to about 20 weight
percent, or
about 8 weight percent. The viscosity enhancing agent of the antibody
composition can
include, e.g., a polyol, such as sucrose or trehalose, or a polymer, such as
hydroxyethyl
-6-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
starch (HES), dextran, dextrin, inulin, or polyvinyl pyrrolidone (PVP). The
sucrose can be
present in the suspension or solution in an amount ranging from about 1 weight
percent to
about 10 weight percent, or about 6 weight percent. The aqueous suspension or
solution of
antibodies can contain both arginine and sucrose. Optionally, the viscosity
enhancing
agents can include PVP.
[0023] A composition containing an antibody bioactive material can be, e.g.,
powder particles with a ratio of excipients (other total solids) to the
antibodies ranging from
about 1/100 to about 100/1, about 2/3 to about 3/2, or about 1/1. The antibody
composition
of powder particles can incorporate, e.g., sucrose in an amount ranging from
about 30
weight percent to about 60 weight percent. The powder particles can contain
less than
about 5 percent moisture.
[0024] The antibodies in powder particles can be quite stable, e.g., with less
than
about 3% aggregates on reconstitution of the powder particles after storage at
about 4°C for
1 year, 5 years or about 7 years. Antibodies dried to powder particles using
methods and
systems of the invention can have, e.g., less than about 3°lo
aggregates on reconstitution of
the powder particles after storage at about 25°C for 0.1 years, 0.5
years, 1 year, or about 1.5
years, or more.
[0025] The antibody compositions of the invention can be reconstituted powder
particles. For example, an aqueous buffer can be added to the powder particles
to form a
reconstituted suspension or solution of antibodies. Such a solution can be,
e.g.,
substantially similar to the suspension or solution sprayed in the process.
Optionally, the
powder particles can be reconstituted with appropriate buffers to provide
desired
characteristics such as isotonicity and/or high antibody concentrations. The
reconstituted
solution or suspension of the antibody can have, e.g., a concentration ranging
from less than
about 0.1 mg/ml to about 500 mg/ml. In a preferred embodiment, the powder
particles can
be reconstituted in 10 minutes or less, e.g., to a concentration of bioactive
material of about
200 mg/ml. In another preferred embodiment, the powder particles can be
reconstituted to a
substantially isotonic suspension or solution containing a bioactive material
concentration
of up to about 200 mg/ml.
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
[0026] A composition of reconstituted antibodies can comprise a 50 mg/ml to
500
mg/ml solution, or more, with less than about 3 percent aggregates or
fragments. In a
preferred embodiment, the antibodies are reconstituted at a concentration of
400 mg/ml or
more. Such compositions can be manufactured by the process of preparing an
aqueous
suspension or solution of the antibodies with a viscosity enhancing agent,
spraying the
suspension or solution through a nozzle at high pressure to form a mist of
fine droplets,
drying the droplets to form powder particles, recovering the particles, and
reconstituting the
particles in an aqueous solution. The composition can be prepared from a
suspension or
solution increased in viscosity with the viscosity enhancing agent by
50°Io, 0.05 centipoise,
or more.
[0027] The compositions of the invention can include, e.g., a polyol and/or
polymer
viscosity enhancing agents. The polyols of the compositions can be, e.g.,
trehalose, sucrose,
sorbose, melezitose, glycerol, fructose, mannose, maltose, lactose, arabinose,
xylose, ribose,
rhamnose, palactose, glucose, mannitol, xylitol, erythritol, threitol,
sorbitol, raffinose,
and/or the like. The polymers of the compositions can be, e.g., starch, starch
derivatives,
carboxymethyl starch, inulin, hydroxyethyl starch (HES), dextran, dextrin,
polyvinyl
pyrrolidone (PVP), human serum albumin (HSA), gelatin, and/or the like. The
suspension
or solution in the process of making the compositions can have viscosity
enhancing agents,
e.g., in an amount between about 0.1 weight percent and about 20 weight
percent, or about 5
weight percent.
[0028] The aqueous solution or suspension sprayed in the process of the
composition can include, e.g., zwitterions, such as arginine, histidine,
glycine, and/or the
like. Arginine can be present in the process suspension or solution in an
amount, e.g.,
between about 0.1 weight percent to about 5 weight percent, or about 2 weight
percent. In a
preferred embodiment, the compositions of the invention are prepared from
suspensions or
solutions containing sucrose at concentrations ranging from about 2% to about
8% and
arginine at concentrations ranging from about 2°lo to about 0.5%.
[0029] The aqueous solution or suspension sprayed in the process of the
composition can include, e.g., a surfactant. The surfactant can be, e.g.,
polyethylene glycol
sorbitan monolaurates, polyoxyethylenesorbitan monooleates, block polymers of
_g_
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
polyethylene and polypropylene glycol, e.g., Tween 80, Tween 20, Pluronic F68,
and/or the
like.
[0030] The present invention provides processes of making compositions by high
pressure spraying, e.g., with atomizing high pressure nitrogen gas, and/or
into a cold fluid.
The process for preparing the composition can provide, e.g., immersion of the
fine droplets
in a cold fluid, thereby freezing the droplets, then drying the droplets by
applying a vacuum
and raising a temperature of the droplets.
[0031] Powder particles of the composition can vary, e.g., in average particle
diameter (size), formula, and component proportions. For example, the average
size of the
powder particles can range from about 0.1 ~m to about 100 ~,m, or from about 2
~m to
about 10 pm. The powder particles can contain sucrose in an amount ranging
from about
weight percent to about 60 weight percent, or about 40 weight percent. The
powder
particle composition can contain arginine ranging in concentration from about
1 % to about
20% by weight, or about 5% by weight. The composition of powder particles can
contain
15 PVP ranging in concentration from about 0% to about 5%, or about 0.5% to
about 2% by
weight.
[0032] The size of spray droplets can be controlled in systems and methods of
the
invention by adjusting one or more parameters. For example, the size of
droplets or
particles can be controlled by adjusting the percent surface active agent in
the suspension or
20 solution, adjusting a spraying pressure, adjusting an atomizing gas
pressure, adjusting a
viscosity, adjusting the total solids in the suspension or solution, adjusting
a flow rate of the
suspension or solution, adjusting a mass flow ratio, adjusting a temperature
of the
suspension or solution, and/or the like.
[0033] Compositions of the invention include, e.g., dry powder particles with
an
average particle size ranging from about 2 ~.m to about 200 ~m , a particle
density of about
1, and 40 weight percent to about 60 weight percent antibodies with more than
about 90
percent purity (non-aggregated and non-fragmented). In preferred embodiments
the particle
size is less than 10 ~,m and the antibody purity is 97% or more. The
composition of dry
particles can be stable with, e.g., antibodies less than about 3% aggregated
on reconstitution
-9-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
of the powder particles after storage at about 4°C for about 1 year to
about 7 years. The
composition of powder particles on reconstitution after storage at about
25°C for about 0.1
years to about 1.5 years can have, e.g., less than about 3% aggregates. Such
powder particle
compositions can include, e.g., about 40 weight percent to about 60 weight
percent sucrose
or trehalose, and/or arginine.
[0034] In a preferred composition of the invention, particles containing a
virus are
prepared by: preparing an aqueous suspension or solution containing the virus
and sucrose,
spraying the suspension or solution through a nozzle at high pressure to form
a mist of fine
droplets, drying the droplets to form powder particles, and recovering the
particles. The
presence of the viscosity enhancing agent in the suspension can increase
viscosity by 50%,
0.05 centipoise, or more. High pressure spraying can be by atomization with a
gas at
temperatures and pressures at least 10% away from a critical point for the
gas. The virus
can include influenza virus. Using the methods and formulations of the
invention, viability
of the virus is not reduced significantly in the recovered particles.
DEFINITIONS
[0035] Before describing the present invention in detail, it is to be
understood that
this invention is not limited to particular described methods or biological
materials, which
can, of course, vary. It is also to be understood that the terminology used
herein is for the
purpose of describing particular embodiments only, and is not intended to be
limiting. As
used in this specification and the appended claims, the singular forms "a",
"an" and "the"
can include plural referents unless the content clearly dictates otherwise.
Thus, for
example, reference to "a polyol" can include a combination of two or more
polyols;
reference to "bacteria" can include mixtures of bacteria, and the like.
[0036] Unless defined otherwise, all technical and scientific terms used
herein have
the same meaning as commonly understood by one of ordinary skill in the art to
which the
invention pertains. Although any methods and materials similar or equivalent
to those
described herein can be used in the practice for testing of the present
invention, the
preferred materials and methods are described herein. In describing and
claiming the
-10-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
present invention, the following terminology will be used in accordance with
the definitions
set out below.
[0037] The term "particle size", as used herein, generally refers to the
average
physical diameter of particles.
[0038] The term "specific activity", in the context of bioactive materials of
the
invention refers to the bioactivity relative to the amount of agent. A highly
pure,
undenatured bioactive material can have, e.g., a high specific activity. A
denatured
bioactive material can have a low specific activity.
[0039] The term "high pressure spraying", as used herein, refers to spraying a
suspension or solution fed through an orifice at a pressure greater than used
for standard
spray dryers. High pressures can be, e.g., greater than about 200 psi.
Preferred high
pressure spraying pressures range from about 1000 psi to about 2000 psi. High
pressure
spraying can include, e.g., atomization of the suspension or solution with a
gas at a pressure
more than 10% away from a critical point for the gas.
[0040] The term "viscosity enhancing agent", as used herein, refers to
molecular
species in the suspensions or solutions of the invention that significantly
increase the
viscosity of the suspension or solution. Preferred viscosity enhancing agents
include, e.g.,
polyols, polymers, sugars, and polysaccharides.
BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 shows a chart comparing droplet size versus mass flow ratio
(MFR)
for solutions sprayed at high pressure versus solutions sprayed at lower
pressures.
[0042] Figure 2 shows a chart presenting critical temperature and pressure
points of
phase transition for a gas.
[0043] Figure 3 shows chart of droplet size versus atomization pressure for a
solution containing viscosity enhancing agents and/or surface active agents.
[0044] Figures 4A and 4B show charts of dry powder particle size versus mass
flow
ratio and atomization pressure, respectively.
-11-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
[0045] Figure 5 is a schematic diagram of an exemplary high pressure spray
nozzles.
[0046] Figure 6 shows a chart of droplet size versus liquid feed rate for
combinations of pressures and atomizing nozzle orifice internal diameters.
[0047] Figure 7 shows chromatographic charts indicating the viscosity
enhancing
agent prevention of denaturation in the high pressure spray-drying process.
[0048] Figure 8 shows chromatographic charts indicating the high purity, high
concentration, and high stability of reconstituted compositions of the
invention.
[0049] Figure 9 is a schematic diagram of an exemplary high pressure spray dry
system.
DETAILED DESCRIPTION
[0050] The present invention provides compositions and methods for preparing
stable particles containing bioactive materials. The method provides, e.g.,
quick drying of
droplets into particles without high heat by using high spray pressures to
inject a fine mist
into a warm stream of drying gas. The compositions of the invention provide
viscosity
enhancing agents to reduce shear stress on bioactive materials during the
spraying process.
[0051] The method of the invention provides, e.g., spray drying of bioactive
materials in a composition with viscosity enhancing agents at a high pressure
to produce
fine droplets that dry quickly to powder particles with little initial loss of
in purity or
viability. The high initial purity and protective effects of excipients
provide, e.g., a long
shelf life and excellent stability for powder particles storage. The fine
powder particles and
highly soluble excipients allow ready reconstitution of bioactive materials to
a high
concentration with high specific activity.
METHODS OF HIGH PRESSURE SPRAY DRYING
[0052] Methods of the invention combine high pressure spraying with protective
formulations for fast drying of pure and stable bioactive materials. The
methods of the
invention include production of powder particles containing bioactive
materials, e.g., by
preparing an aqueous suspension or solution of the bioactive material with a
viscosity
-12-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
enhancing agent, spraying the suspension of solution through a nozzle at high
pressure to
form a mist of fine droplets, drying the droplets to form powder particles,
and recovering
the particles for storage or immediate use.
[0053] The methods can be modified to provide suitable products depending on,
e.g., the sensitivity of the bioactive material, the expected storage
conditions, and the
proposed route of administration. A variety of viscosity enhancing agents,
such as, e.g.,
polyols and polymers, are available which can provide desirable
characteristics, in addition
to shear stress protection, including antioxidation, hydrogen bonding with the
bioactive
material to replace water of molecular hydration, high solubility to aid in
reconstitution, and
safety for injection in humans. High pressure to spray suspensions or
solutions of the
bioactive material can be provided, e.g., by hydraulic pressure, pressurized
gases, or high
pressure pumps, such as HPLC pumps. Drying of droplets can be achieved, e.g.,
by
freezing and sublimation, warm streams of humidity controlled inert gasses,
and/or
suspension in a fluidized bed. Recovering the particles can include separation
of particles
by size, filtering, settling, filling into sealed containers; and the like.
Particles of the
invention can be used, e.g., to administer the bioactive material by
inhalation, to reconstitute
for administration by injection, to store analytical reference samples for
long term
references, and/or the like.
Preparing a Suspension or Solution of Bioactive Materials
[0054] A bioactive material of interest can be added to a solution comprising
a
viscosity enhancing agent to prepare the suspension or solution of the
invention. Additional
excipients can be added to enhance solubility of components, reduce oxidation,
add bulk,
reduce surface tension, reduce the porosity of the particles, control pH,
and/or the like.
[0055] The bioactive materials of the invention can be, e.g., industrial
reagents,
analytical reagents, vaccines, pharmaceuticals, therapeutics, and the like.
Bioactive
materials of the invention include, e.g., peptides, polypeptides, proteins,
viruses, bacteria,
antibodies, monoclonal antibodies, cells, or liposomes. Preparation steps for
liquid
formulations of these materials can vary depending on the unique sensitivities
of each
material.
-13-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
[0056] Liquid formulations for spraying can be prepared by mixing the
bioactive
material, viscosity enhancing agent, and other excipients, in an aqueous
solution. Some
bioactive materials, such as, e.g., many peptides and antibodies, dissolve
readily into an
aqueous solution. Other bioactive materials, such as, e.g., viruses, bacteria,
and liposomes
can be particles that exist as a suspension in the formulation. Whether the
bioactive
material provides a solution or suspension, it is often necessary, e.g., to
avoid severe
conditions of shear stress or high temperatures when mixing them into a
formulation.
Where other formulation constituents require heat or strong stirring to bring
into solution,
they can, e.g., be dissolved separately then gently blended with the bioactive
material after
cooling.
[0057] The total solids in the final suspension or solution is generally,
e.g., high, to
help provide the high viscosity and quick low temperature drying aspects of
the invention.
For example, process suspensions or solutions for spraying in the invention
can include
from about 5 percent to about 50 percent total solids, from about 10 percent
to 20 percent
total solids, or about 15 percent total solids. The suspensions or solutions
for high pressure
spraying can have a viscosity significantly greater than that of water at room
temperature
(0.01 poise), and greater than the viscosityof the bioactive material
suspension or solution
without addition of the viscosity enhancing agent. For example, addition of
the viscosity
enhancing agent can increase the viscosity of the suspension or solution for
spraying by
0.02 centipoise, 0.05 centipoise, 0.1 centipoise, 0.5 centipoise, 1
centipoise, 5 centipoise, 10
centipoise, 0.5 poise, 1 poise, 5 poise, 10 poise, or more. In another aspect,
addition of the
viscosity enhancing agent can increase the viscosity of the suspension or
solution for
spraying by 1%, 5%, 25%, 50%, 100%, 500%, or more. In a preferred embodiment,
viscosity enhancing agents are present at a concentration sufficient to
increase the viscosity
by 0.05 centipoise or more, or sufficient to increase the viscosity of the
suspension or
solution by 5% or more.
[0058] The concentration of bioactive material in the suspension or solution
can
vary widely, depending, e.g., on the specific activity, concentration of
excipients, route of
administration, and/or intended use of the material. Where the bioactive
material is a
peptide vaccine, live virus, killed virus for vaccination, or bacteria, for
example, the
-14-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
required concentration of material can be quite low. Where the bioactive
material is, e.g.,
an antibody for therapeutic administration by inhalation, or a liposome for
topical
administration, the required concentration can be higher. In general,
bioactive materials can
be present in the solutions or suspensions of the invention at a
concentration, e.g., between
less than about 1 mg/ml to about 200 mg/ml, from about 5 mg/ml to about 80
mg/ml, or
about 50 mg/ml. Viral particles can be present in the suspensions or solutions
in amounts,
e.g., ranging from about 10 pg/ml to about 50 mg/ml or about 10 ug/ml.
[0059] Viscosity enhancing agents of the invention are generally, e.g., sugars
or
water soluble polymers which can be dissolved or effectively suspended into
the solution or
suspension at concentrations high enough to provide significant protection
against shear
disruption or denaturation of the bioactive material. In general, effective
amounts of
viscosity enhancing polymers are lower than for sugars due to the higher
viscosity produced
by longer molecules in solution. Viscosity enhancing agents can be present in
the
suspensions or solutions of the invention in amounts, e.g., between about 0.05
weight
percent to about 30 weight percent, from about 0.1 weight percent to about 20
weight
percent, or about 2 weight percent to about 6 weight percent. Many viscosity
enhancing
agents are carbohydrates that can provide, e.g., protective effects to
bioactive materials
under other process stresses, such as, e.g., freezing and drying.
[0060] The suspension or solution of the invention can include, e.g., a
surfactant
compatible with the particular bioactive material involved. A surfactant can
enhance
solubility of other formulation components to avoid aggregation or
precipitation at higher
concentrations. Surface active agents can, e.g., lower the surface tension of
the suspension
or solution so that bioactive materials are not denatured at gas-liquid
interfaces, and/or so
that spraying forms finer droplets. Surfactants can be present in the
solutions or
suspensions of the invention in an amount ranging from about 0.005 percent to
about 1
percent, from about 0.01 percent to about 0.5 percent, or about 0.02 percent.
Spray~ the Su~ension or Solution
[0061] Suspensions or solutions of the invention are sprayed, e.g., from a
spray
nozzle at high pressure to produce a fine mist of droplets. Spray parameters
can vary, e.g.,
-15-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
according to the viscosity of the solution, the desired particle size, the
intended method of
drying, the design of atomization nozzles, and/or sensitivities of the
bioactive material.
[0062] High pressure spraying has significant advantages over lower pressure
spraying methods to obtain fine droplets, and ultimately, fine dry powder
particles. As
shown in Figure 1, high pressure spraying (plot 10) can provide droplet sizes
less than 10
pm with mass flow ratios (MFR - the ratio of atomizing gas mass flow per
liquid mass
flow) less than 1, whereas standard (lower pressure atomizing nozzles, plot
11) can require
MFRs in the range of about 15 to obtain droplet sizes less than 10 p,m. High
pressure
spraying can provide a significant reduction in the use of atomizing gasses
while spraying
finer average droplet sizes than obtainable with lower pressure spray methods.
Optionally,
high pressure spraying can be practiced without simultaneous discharge of
atomizing gas,
i.e., spraying of high pressure liquid from a nozzle without a jet of gas.
[0063] The suspension or solution can be sprayed from a nozzle at a pressure
effective in providing the desired droplet size. Higher pressures generally
provide, e.g.,
smaller droplet sizes. When the solution is more viscous, e.g., a higher
pressure can be
required to provide the desired droplet size. The presence of a surfactant,
e.g., often lowers
the pressure required to provide the desired droplet size in high pressure
spraying processes.
Where suspensions or solutions are atomized by spraying in the presence of a
pressurized
gas flow, the mass flow ratio can affect droplet sizes. The spray pressures of
the invention
can be, e.g., between about 200 psi and about 5000 psi, between about 500 psi
and 1500 psi,
or about 1300 psi. The size of spray droplets and/or dried particles can be
controlled by,
e.g., adjusting the percent surface active agent in the suspension or
solution, adjusting a
spraying pressure, adjusting an atomizing gas pressure, adjusting a viscosity,
adjusting the
total solids in the suspension or solution, adjusting a flow rate of the
suspension or solution,
adjusting a mass flow ratio, adjusting a temperature of the suspension or
solution, and/or the
like.
[0064] Where the spray of droplets is atomized with a high pressure atomizing
gas,
the atomizing gas can have, e.g., a pressure or temperature at least 10%, or
at least 15%, or
at least 20%, away from a critical point for the gas. As shown in Figure 2,
pressurization
and/or cooling of many gasses can lead to a phase transition from the gas
state to a liquid or
-16-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
solid state. These transitions from the gas state can take place at critical
pressures and/or
critical temperatures. It is an aspect of the invention that in some
embodiments, atomizing
gasses are more than 10%, or more than 15%, below the critical pressure for
the gas at a
given temperature. It is an aspect of the invention that in some embodiments,
atomizing
gasses are more than 10%, or more than 15%, above the critical temperature (as
measured in
degrees Kelvin) for the gas at a given pressure.
[0065] In one embodiment, the suspension or solution includes both a viscosity
enhancing agent and a surface active agent, e.g., to provide improved control
of sprayed
droplet size at a given spray pressure. In the presence of viscosity enhancing
agents,
sprayed droplet sizes are generally greater than for solutions without
viscosity enhancing
agents. In the presence of surface active agents, sprayed droplet sizes are
generally smaller
than for solutions without surface active agents. However, when suspensions or
solutions
include both a viscosity enhancing agent and a surface active agent, some
useful and
unexpected results can be obtained. A chart of droplet size versus atomization
pressure can
be prepared to show relationships between pressures, surface active agents,
viscosity
enhancing agents and droplet sizes, as shown for example in Figure 3. At some
pressures,
e.g., 900 to 1100 psi, pure water 30 can spray into smaller droplet sizes than
for water with
surface active agent (Tween 80) and/or viscosity enhancing agent (Sucrose). At
other
pressures, e.g., from about 1300 psi to about 2200 psi, solutions or
suspensions containing
surface active agent can spray into droplet sizes smaller than for pure water.
At a certain
enhanced surfactant control ranges of spray pressures, surface active agents
can exert a
particularly significant influence on the droplet size of solutions or
suspensions containing
viscosity enhancing agents. For example, at 1500 psi the average droplet size
of 20%
sucrose solution 31 can be more than for water at about 14 pm, but the average
droplet size
can be less than for water at about 8 ~m for 20% sucrose solution with 0.1%
Tween 80 32.
In one embodiment of the invention, the droplet size of sprayed suspensions or
solutions is
controlled at a particular atomization pressure by adjustment of the surface
active agent
concentration. For example, incremental adjustments of surface active agent
concentrations
can provide tuned droplet sizes even if other parameters, such as orifice
internal diameter,
viscosity enhancing agent concentration, pressure, and MFR are held constant.
Enhanced
-17-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
surfactant control ranges can be determined empirically for bioactive agent,
surface active
agent, viscosity enhancing agent combinations of interest.
[0066] Droplet sizes can be affected by the mass flow ratio (MFR) of atomizing
gas
and the suspension or solution. Under conditions of low MFR for a given
atomizing
pressure, as shown on the left side of the chart in Figure 4A, larger
particles are formed.
Under conditions of higher MFR for a given atomizing pressure, as shown on the
right side
of the chart, smaller powder particles are formed on drying of the sprayed
droplets. One
explanation for this observation is that higher relative flows of atomizing
gas are able to
disrupt a given fluid flow into smaller droplets. In many cases, average
droplet size (and
final dried particle sizes) can be tuned by adjusting the flow rate of a
suspension or solution
to be high pressure sprayed while any atomizing gas pressure remains constant.
Optionally,
the MFR can be varied to adjust droplet size by varying the pressurized
atomizing gas flow
while the flow of suspension or solution is held constant, as shown in Figure
4B.
[0067] In a preferred embodiment, suspensions or solutions are high pressure
spray-
dried with an atomizing stream of pressurized nitrogen gas. Atomization with
the nitrogen
gas stream can contribute to reduced droplet sizes as a given pressure as
compared to direct
high pressure spraying without a atomizing gas. Nitrogen has an advantage over
atomization with pressurized air in that it is relatively inert and can
protect bioactive
materials, e.g., from oxidation. Nitrogen has advantages over carbon dioxide
in that it does
not form acids in aqueous solutions and has a greater capacity to hold water
vapor.
Nitrogen is less expensive than other substantially inert gasses. Appropriate
nozzles for
high pressure spraying with atomizing nitrogen include, e.g., dual channel
atomizing
nozzles and nozzles with T intersections of liquid with the atomizing gas. As
shown in
Figure 4B, particle sizes of dried droplets generally decrease with higher
atomization
pressures at a given MFR.
[0068] High pressure spray drying processes can be scaled up, e.g., by
spraying
larger volumes of suspensions or solutions. Larger volumes can be sprayed,
e.g., by using
multiple spray nozzles, by spraying at higher pressures, and/or by spraying
through a larger
internal diameter spray orifice. Figure 5 shows some examples of high pressure
spray
nozzle configurations. Figure SB shows a high pressure liquid spray nozzle
with a
-18-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
constrictor at the orifice. When spraying from an atomizing nozzle, e.g., as
shown in
Figures SA and 5C, the MFR can change with the flow rate of the suspension or
solution
resulting with changed droplet sizes at a given atomizing gas pressure. This
is because as
the flow rate of the liquid increases, the flow of atomizing gas can become
restricted. For
example, as shown in Figure 6, as the liquid feed rate increases for a
suspension or solution
being atomized with a 2500 psi gas through a 250 ~.m orifice, the droplet size
begins to
increase in a nonlinear fashion at a liquid flow rate of about 30 ml/min (plot
60). This is
due to restriction of the atomizing gas flow by the flow of liquid and
resultant drop in the
MFR. Such a rapid increase in droplet size can be delayed by employing an
atomizing
nozzle with a larger orifice internal diameter, as shown in plot 61 for a
suspension or
solution being atomized with a 1170 psi gas through a 500 ~m orifice.
[0069] Molecular and cellular bioactive materials sensitive to shear stress
can
experience denaturation when sprayed at high pressure. This denaturation can
be reduced,
e.g., by spraying with a viscosity enhancing agent. Figure 7, for example,
shows size
exclusion analyses of a solution of antibodies before and after spray drying.
Figure 7A
shows a size exclusion chromatograph of the antibody before spraying. Figure
7B shows a
size exclusion chromatograph of the antibody after spraying without effective
amounts of a
viscosity enhancing agent, wherein the amount of aggregate 70 has increased
about 6-fold
and fragments 71 have increased slightly. Aggregates of the antibody have a
lowered
specific activity due to shear stress denaturation of the antibody protein and
associated
abnormal hydrophobic interactions between the antibody molecules. Figure 7C
shows a
size exclusion chromatograph of the same antibody which has been protected
from
aggregation and fragmentation by including a viscosity enhancing agent in the
solution
before spraying.
[0070] The spray nozzle of the invention can be adapted to provide the desired
fine
mist of droplets. The nozzle can have, e.g., a conduit feeding the suspension
or solution at
high pressure to a spray orifice that has an internal diameter of between
about 50 pm and
about 500 pm, between about 75 p,m and about 250 Vim, or about 100 pm. Wider
diameter
orifices can provide, e.g., higher production rates but can result in larger
droplet sizes. The
-19-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
nozzle can be configured as an atomizer, i.e., with a second channel routing a
pressurized
gas into the stream of suspension or solution, to aid in the dispersal of the
droplets.
[0071] The process suspension or solution can be sprayed from the nozzle at
high
pressure to form fine droplets that are readily dried into desired powder
particles of the
invention. The droplets can be sprayed, e.g., into a stream of inert warm
drying gas, into a
vacuum of 200 Torr or less, or into a freezing stream of a cold fluid. The
droplets can have
an average diameter of about 2 ~m to about 200 Vim, about 3 ~m to about 70
~.m, about 5
~m to about 30 pm, or about 10 Vim. If the droplets are frozen, e.g., in a
cold stream of
gaseous or liquid, argon, helium, carbon dioxide, or nitrogen, at between
about -80°C to
about -200°C, they can be dried by sublimation to form particles about
the same size as the
droplets but having a low density. If the suspension or solution is high in
total solids, the
dried particles can be, e.g., larger and/or more dense.
Drying the Droplets
[0072] Sprayed droplets can be dried to form powder particles. Droplets can be
dried, e.g., without excessively hot temperatures to provide high recovery of
particles with
high purity, high specific activity, and high stability. Drying can be, e.g.,
by exposure to a
temperature, humidity, and/or pressure controlled environment. Drying can be
by
sublimation of ice, vacuum drying, contact with drying gasses, suspension in a
fluidized
bed, retention in a drying chamber, and/or the like. Primary drying generally
includes, e.g.,
removal of liquid or ice water from the droplets of the suspension or
solution. Secondary
drying generally includes, e.g., removal of excess moisture and/or water of
hydration from
particles to a level of 10 percent residual moisture, 5 percent residual
moisture, or less.
[0073] Drying can be by, e.g., spraying the droplets into a stream of humidity
and
temperature controlled gas. Drying parameters can be controlled, e.g., to
provide conditions
necessary to obtain particles with the desired activity, density, residual
moisture, and/or
stability. The gas can be, e.g., an inert gas, such as nitrogen, that
displaces the water vapor,
and other gases emanating from the sprayed mist of suspension or solution. The
gas can be
dry, e.g., with a low relative humidity, to absorb moisture and speed
evaporation of the
droplets. The gas can be, e.g., controlled to a temperature between about
15°C and about
-20-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
70°C, between 25°C and about 60°C, or about 35°C
to about 55°C. Drying temperatures
can remain, e.g., below the glass transition temperature (Tg) of the particle
constituents to
avoid changing the porosity, density, stability, and/or reconstitution time of
the particles.
The small particle sizes and high total solids of the invention can, e.g.,
allow for short
drying times and cooler drying temperatures that will not substantially
degrade many
sensitive bioactive materials.
[0074] The droplets can be dried, e.g., by application of a vacuum (gas
pressures
less than atmospheric pressure, such as 200 Torr, or less) to the sprayed mist
or partially
dried particles. Vacuum drying has the benefit, e.g., of quickly "boiling" or
sublimating
away water from the droplets while reducing the temperature. The temperature
of the
droplets falls as latent heat is lost during the phase transition of liquid
water to gas. Thus,
vacuum drying can significantly reduce heat stress on the bioactive material.
In the case of
droplets frozen in a stream of cold fluid, or frozen by the loss of latent
heat during drying
processes, vacuum pressures can sublimate water directly from the solid ice
phase to the gas
phase providing freeze-dried (lyophilized) particles.
[0075] Secondary drying conditions can be used, e.g., to further lower the
moisture
content of particles. Particles can be collected in a chamber and held at a
temperature
between about 20°C and about 99°C, about 25°C and about
65°C, or about 35°C and 55°C,
e.g., in a vacuum, for from about 2 hours to about 5 days, or about 4 hours to
about 48
hours, to reduce residual moisture. Secondary drying can be accelerated by
providing an
updraft of drying gasses in the chamber to create a fluidized bed suspension
of powder
particles. Particles with lower residual moisture generally show better
stability in storage
with time. Secondary drying can continue until the residual moisture of the
powder
particles is between about 0.5 percent and about 10 percent, or less than
about 5 percent. At
very low residual moisture values, some bioactive molecules can be denatured
by loss of
water molecules of hydration. This denaturation can often be mitigated by
providing
hydrogen binding molecules, such as sugars, polyols, and/or polymers, in the
process
suspension or solution.
[0076] Powder particles of the invention can have a size, e.g., suitable to
the
handling, reconstitution, and/or administration requirements of the product.
For example,
-21-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
powder particles of bioactive materials for administration by intranasal
delivery by
inhalation can be larger, at between about 20 ~m to about 150 ~m or more, than
for deep
pulmonary delivery by inhalation, at between about 2 ~m to about 10 Vim. The
particle size
for products that reconstitute slowly can be smaller to speed dissolution of
the particles.
Spray freeze-dried particles can have, e.g., a lower density, because the ice
can be removed
from droplets without collapse of a cake structure of the remaining solids.
Such particles
can have, e.g., a physically larger size for inhaled administration due to
their lower
aerodynamic radius. Freeze-dried particles can, e.g., be larger than particles
dried from
liquid droplets and still retain quick reconstitution properties due to the
porous nature of
freeze-dried particles. Freeze dried powder particles of the invention can
have average
physical diameters, e.g., between about 0.1 p,m and about 200 pm, or between
about 2 pm
and about 100 pm, or about 10 ~,m.
[0077] The average size and size uniformity of particles can be controlled,
e.g., by
adjusting spraying parameters and/or by adjusting drying parameters. For
example, average
droplet size can be affected by nozzle size, solution pressures, solution
viscosity, and
solution constituents, etc., as described above in the Spraying the Suspension
or Solution
section above. Average particle size, and size distribution, can be affected
by drying
conditions that affect shrinkage or agglomeration of particles, such as, e.g.,
the use of
freeze-drying, the completeness of drying, the neutralization of static
charges, particle
density during drying, the rate of drying, the temperature of drying, and/or
the like. The
average size and size uniformity of particles can be selected as described in
the Recovery of
Particles section, below.
Recovery of Particles
[0078] Powder particles of the invention can be physically recovered from the
process stream, e.g., by settling or filtration. The recovery of bioactive
material activity of
the in the process is the product of the physical recovery times the specific
activity of
recovered agent.
[0079] Physical recovery of powder particles can depend, e.g., on the amount
of
material retained or expelled by the spray-drying equipment and losses
incurred due to
-22-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
particle size selection methods. For example, material containing the
bioactive material can
be lost in the plumbing, and on surfaces of the spray-drying equipment.
Solution or
particles can be lost in the process, e.g., when an agglomeration of spray
droplets grows and
falls out of the process stream or when under sized droplets dry to minute
particles that are
carried past a collection chamber in a process waste stream. Process yields
(the percent
recovery of input bioactive material through the process) of the invention can
range, e.g.,
from about 40 percent to about 98 percent, or more, or about 90 percent.
[0080] Particles of a desired average size and size range, can be selected,
e.g., by
filtration, settling, impact adsorption, and/or other means known in the art.
Particles can be
sized by screening them through one or more filters with uniform pore sizes.
Large
particles can by separated by allowing them to fall from a suspension of
particles in a
moving stream of liquid or gas. Smaller particles can be separated by allowing
them to be
swept away in a stream of liquid or gas moving at a rate at which larger
particles settle.
Large particles can be separated by surface impact from a turning gas flow
that carries away
particles with less momentum.
[0081] Recovery of active bioactive material can be affected, e.g., by
physical
losses, agent disruption, denaturation, aggregation, fragmentation, oxidation,
and/or the like,
experienced during the spray-dry process. The methods of the invention offer
improved
recovery of bioactivity over the prior art, e.g., by providing spray dry
techniques that reduce
shear stress, reduce drying time, reduce drying temperatures, and/or enhance
stability. For
example, monoclonal antibodies spray dried by the methods of the invention can
experience
less than 4 percent aggregation and fragmentation on initial production and in
storage for up
to about 7 years at 4°C. Methods of the invention can provide dried
powder having
bioactive material substantially unchanged activity or viability compared to
the same
bioactive material in the suspension or solution before high pressure
spraying.
Administration of the Bioactive material
[0082] Where it is appropriate, the bioactive material of the invention can be
administered, e.g., to a mammal. Bioactive materials of the invention can
include, e.g.,
peptides, polypeptides, proteins, viruses, bacteria, antibodies, cells,
liposomes, and/or the
-23-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
like. Such agents can act as therapeutics, nutrients, vaccines,
pharmaceuticals,
prophylactics, and/or the like, that can provide benefits on administration to
a patient, e.g.,
by gastrointestinal absorption, topical application, inhalation, and/or
injection.
[0083] The bioactive material can be administered to a patient by topical
application. For example, the powder particles can be mixed directly with a
salve, Garner
ointment, and/or penetrant, for application to the skin of a patient.
Alternately, the powder
particles can, e.g., be reconstituted in an aqueous solvent before admixture
with other
ingredients before application.
[0084] Bioactive materials of the invention can be administered by inhalation.
Dry
powder particles about 10 ~m in aerodynamic diameter, or less, can be inhaled
into the
lungs for pulmonary administration. Optionally, powder particles about 20 Vim,
and greater,
in aerodynamic diameter can be administered intranasally, or to the upper
respiratory tract,
where they are removed from the air stream by impact to the mucus membranes of
the
patient. The powder particles can alternately be reconstituted to a suspension
or solution for
inhalation administration as an aqueous mist.
[0085] Bioactive materials of the invention can be administered by injection.
The
powder particles can be administered directly under the skin of a patient
using, e.g., a jet of
high pressure air. More commonly, the powder particles can be, e.g.,
reconstituted with a
sterile aqueous buffer for injection through a hollow syringe needle. Such
injections can be,
e.g., intramuscular, intra venous, subcutaneous, intrathecal, intraperitoneal,
and the like, as
appropriate. Powder particles of the invention can be reconstituted to a
solution or
suspension with a bioactive material concentration of from less than about 1
mg/ml to about
500 mg/ml, or from about 5 mg/ml to about 400 mg/ml, as appropriate to the
dosage and
handling considerations. Reconstituted powder particles can be further
diluted, e.g., for
multiple vaccinations, administration through IV infusion, and the like.
COMPOSITIONS OF THE INVENTION
[0086] Compositions of the invention are generally bioactive materials in dry
powders prepared using the methods of the invention. Numerous combinations of
bioactive
-24-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
materials, processing steps, process parameters, and composition constituents,
as described
herein, are available to suit the intended use of the composition.
[0087] The compositions of the invention provide, e.g., powder particles
containing
a bioactive material which are made by preparing an aqueous suspension or
solution of the
bioactive material and a viscosity enhancing agent, spraying the suspension or
solution
through a nozzle at high pressure to form a mist of fine droplets, drying the
droplets to form
powder particles, and recovering the particles, as is described in the Methods
sections,
above. In a particular embodiment of the composition, the powder particles
contain
antibodies as the bioactive material which can be reconstituted into a 400
mg/ml solution, or
more, with the antibodies having less than about 3 percent aggregates or
fragments. The
compositions of the invention include, e.g., stable powder particles and
highly concentrated
solutions of bioactive materials with high purity and high specific activity.
Powder particles
containing viral bioactive materials can be prepared by high pressure spraying
a suspension
of the virus, sucrose, and a surface active agent.
Powder Particles
[0088] Powder particles of the composition are dried droplets of the process
suspensions or solutions of the invention. The particles include, e.g., stable
bioactive
materials in a dried matrix of excipients, such as the polyol and/or polymer
viscosity
enhancing agents. The particles range in average physical diameter (size),
e.g., from about
0.1 p,m to about 100 pm, about 2 ~m to about 10 Vim, or about 4 Vim. The
bioactive
material is present in the powder particles in a ratio ranging, e.g., from
less than about 1/100
to about 100/1, about 1/5 to about 5/l, or about 2/3 to about 3/2, with
respect to excipients,
by weight. In one embodiment, a composition of the invention comprises dry
powder
particles averaging about 5 ~m in diameter with about 55 weight percent
monoclonal
antibody, about 15 weight percent arginine, about 2 weight percent polyvinyl
pyrrolidone,
about 33 weight percent sucrose, and about 5% moisture. In another embodiment,
the
composition of dry powder particles includes, e.g., a live attenuated virus at
about 0.01% by
weight, about 15 percent arginine, 70 percent polyol, and less than 5 percent
moisture.
-25-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
Bioactive materials
[0089] Bioactive materials of the composition include, for example, peptides,
polypeptides, proteins, viruses, bacteria, antibodies, cells, liposomes,
and/or the like.
Bioactive materials in the powder particles of the invention can be, e.g.,
highly pure and
active at the time of drying the powder particles, due to the reduced shear
stress, the low
drying temperatures, protective excipients, and the short drying times used in
their
preparation. Bioactive materials are, e.g., stable in the powder particles due
to the low
initial process degradation and protective aspects of the composition
excipients. Bioactive
materials of the composition can be, e.g., reconstituted at high
concentrations without
degradation due to the high surface to volume ratio of the particles and the
solubility
enhancements provided by the excipients of the composition.
[0090] Solutions or suspensions high pressure spray-dried to form the powder
particles of the invention contain, e.g., the bioactive materials of the
invention in an amount
ranging from less than about 1 mg/ml to about 200 mg/ml, from about 5 mg/ml to
about 80
mg/ml, or about 50 mg/ml. Bioactive materials in the dry powder particles of
the invention
are present in amounts ranging, e.g., from less than about 0.1 weight percent
to about 80
weight percent, from about 40 weight percent to about 60 weight percent, or
about 50
weight percent. Bioactive materials of the reconstituted composition can be
present in
concentrations ranging, e.g., from less than about 0.1 mg/ml to about 500
mg/ml, from
about 5 mg/ml to about 400 mg/ml, or about 100 mg/ml. In one aspect of the
invention, the
bioactive material is a virus present in the suspension to be sprayed at a
titer ranging from
about 2 log FFU/ml to about 12 log FFU/ml, or about 3 log FFU (focus forming
units) to 13
log FFU per gram of dry powder particles.
Viscosity Enhancing Agents
[0091] Viscosity enhancing agents of the composition include, e.g., polyols
and/or
polymers that can provide protection to bioactive materials against shear
stress when the
solutions or suspensions of the invention are sprayed at high pressure. The
viscosity
enhancing agents ultimately become a significant part of the powder particle
bulk and
provide additional benefits. For example, the viscosity enhancing agents in
the particles
-26-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
can, e.g., help stabilize the bioactive material by providing hydrogen bonding
replacement
for water molecules of hydration lost in drying, increase the solubility of
the particles for
quicker reconstitution at high concentrations, provide a glassy matrix to
retard reaction
kinetics, and physically block destabilizing molecules (such as oxygen) from
gaining access
to the bioactive material.
[0092] Polyols useful as viscosity enhancing agents should be, e.g.,
compatible with
the intended use of the composition. For example, particles intended for
injection into
humans should be generally recognized as safe. Viscosity enhancing polyols can
include,
e.g., trehalose, sucrose, sorbose, melezitose, glycerol, fructose, mannose,
maltose, lactose,
arabinose, xylose, ribose, rhamnose, palactose, glucose, mannitol, xylitol,
erythritol,
threitol, sorbitol, raffinose, and/or the like. Non-reducing sugars are
generally
recommended, e.g., where the bioactive material is a peptide, in order to
avoid chemical
modification of the side chains.
[0093] Polymers useful as viscosity enhancing agents can include, e.g.,
starch,
starch derivatives, carboxymethyl starch, inulin, hydroxyethyl starch (HES),
dextran,
dextrin, polyvinyl pyrrolidone (PVP), human serum albumin (HSA), gelatin,
and/or the like.
Many polymers are, e.g., more viscous in solution by weight than polyols so
can often
provide adequate shear stress protection at lower concentrations.
[0094] Viscosity enhancing agents can be present in the solutions or
suspensions of
the invention before spray-drying in amounts between about 0.1 weight percent
to about 20
weight percent, between about 2 weight percent and 8 weight percent, or about
6 weight
percent. In many embodiments, polyol viscosity enhancing agents are present at
about 6
weight percent in the solution or suspension, while polymer viscosity
enhancing agents are
present at about 2 weight percent. Viscosity enhancing agents are preferably
present in the
suspensions or solutions of the inventions at concentrations sufficient to
increase the
viscosity of the suspension or solution by about 5% or more, or by 0.05
centipoise or more.
-27-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
Other Excipients
[0095] The compositions of the invention can include additional excipients to
provide appropriate characteristics and benefits. For example, the
compositions can include
surfactants, zwitterions, buffers, and the like.
[0096] Surfactants can be included in the compositions of the invention, e.g.,
to
increase the solubility of composition constituents, and/or to reduce surface
tension.
Surfactants can, e.g., increase the suspension or solubility of certain
bioactive materials by
surrounding them with charged or hydrogen bonding groups. Surfactants can help
in
reconstitution of powder particles by, e.g., accelerating the dissolution of
the excipient
matrix on exposure to water. By reducing surface tension, surfactants can
reduce
aggregation and conformational changes that can occur with some bioactive
materials at the
air/liquid interface of droplets during spraying. Surfactants of the
compositions can include,
e.g., any appropriate surfactant, such as polyethylene glycol sorbitan
monolaurates,
polyoxyethylenesorbitan monooleates, or block polymers of polyethylene and
polypropylene glycol, e.g., Tween 80, Tween 20, or Pluronic F68. Surfactants
can be
present in the compositions in amounts between about 0.01 weight percent to
about 2
weight percent, between about 0.1 weight percent and 0.5 weight percent, or
about 0.2
weight percent of the powder particles. Surface active agents can provide
benefits in the
control of droplet and particle sizes, as described above.
[0097] Zwitterions, such as amino acids, can be included in the compositions,
e.g.,
as counter ions to charged groups of the bioactive materials or surfactants.
The presence of
these counter ions can, e.g., help the bioactive materials retain non-
denatured
conformations, prevent aggregation, and inhibit adsorption of charged
bioactive materials
onto surfaces of processing equipment. The zwitterions can, e.g., help protect
the bioactive
materials against deamidation reactions, act as antioxidants, and provide pH
buffering
capacity. Zwitterions of the invention can include, e.g., arginine, histidine,
glycine, and/or
the like. Zwitterions can be present in the compositions of the invention in
amounts
between about 0.1 percent and about 10 percent, between about 0.5 percent and
about 5
percent, or about 2 percent of the total solids.
-28-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
[0098] Buffers can be included in the compositions of the invention, e.g., to
control
pH, increase product stability, and/or to increase the comfort of
administration. Buffers of
the composition can include, e.g., phosphate, carbonate, citrate, glycine,
acetate, and the
like.
EXAMPLES
[0099] The following examples are offered to illustrate, but not to limit the
claimed
mvent~on.
EXAMPLE 1 - HIGH PRESSURE SPRAY DRYING OF ANTIBODIES
[0100] An aqueous solution was prepared to contain 8 weight percent of a
monoclonal antibody, 6 weight percent sucrose, 0.2 weight percent PVP, and 2
weight
percent arginine. The solution was sprayed from a nozzle at about 1150 psi to
provide
droplets with an average diameter of about 10 pm. The droplets were dried in a
stream of
dry nitrogen gas ranging in temperature from about 60°C to about 45RC
to produce powder
particles with an average diameter of about 4 pm and a moisture less than 5
percent. The
powder particles were initially reconstituted into solutions with antibody
concentrations of
up to 500 mg/ml and with less than 3 percent total aggregates and fragments.
Figure 8
shows the antibody after reconstitution at high concentrations and storage for
nine days, or
more, at 50°C. The powder particles remained stable with trend analysis
predicting
stability, with less than 3 percent aggregates, over about 7 years in storage
at 4°C, or for
about 1.5 years in storage at 25°C.
[0101] In another example of stability for high pressure spray dried
formulations, an
aqueous solution was prepared to contain 8 weight percent of a monoclonal
antibody, 6
weight percent sucrose, 0.002% Tween 20, and 2 weight percent arginine. The
solution was
sprayed from a nozzle at about 1300 psi into an inlet nitrogen drying gas
temperature of
about 60°C, with a drying chamber outlet temperature of about
45°C. Stability data indicate
the dried powder particles should form only about 1.5% additional aggregates
after more
than 6 years in storage at 4°C or after about 2 years in storage at
25°C.
-29-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
[0102] In another example, a low tonicity, fast dissolving formulation was
high
pressure spray-dried to prepare stable powder particles. An aqueous solution
was prepared
to contain 8 weight percent of a monoclonal antibody, 2 weight percent
sucrose, 0.008%
Tween 20, and 0.5 weight percent arginine for high pressure spraying with
atomizing
nitrogen at 1300 psi into an inlet nitrogen drying gas temperature of about
60°C, with a
drying chamber outlet temperature of about 45°C. The dried powder was
reconstituted to
an antibody concentration of 180 mg/ml with a dissolution time of only 10
minutes using
orbital shaking at room temperature. Such a formulation can have practical
benefits of
quick preparation for injection and reduced pain and irritation at the site of
injection.
Stability data indicate more than 2 years in storage at 4°C before the
formation of 2%
additional aggregates in the dried powder.
EXAMPLE 2 - HIGH PRESSURE SPRAY DRYING OF LIVE VIRUS
[0103] An aqueous solution was prepared of live influenza virus at about 7.5
log
FFU/ml in AV047r (5% sucrose, 2% trehalose, 10 mM methionine, 1% arginine,
0.2%
Pluronic F68, 50 mM KP04, pH 7.2) was high pressure sprayed at 1300 psi into a
drying
chamber with a 55°C inlet temperature. Reconstitution of the dry powder
showed no
significant viability loss with a titer of about 7.5 log FFU/ml. The
formulation required 23
days at a 37°C accelerated storage temperature to experience a 1 log
loss of viability.
EXAMPLE 3 - A HIGH PRESSURE SPRAY DRY SYSTEM
[0104] A high pressure spray drying system can include, e.g., a high pressure
pumping system to deliver suspension or solution to a high pressure spray
nozzle, and a
spray drying system to carry droplets and particles in a stream of conditioned
gasses. As
shown in Figure 9, suspension or solution 90, with a bioactive material and
viscosity
enhancing agent, is transferred from a holding container to high pressure
spray nozzle 91
using high pressure pump 92. High pressure gas from gas source 93 is pumped
through
high pressure gas pump 94 to atomize the suspension or solution into a fine
mist spray of
droplets 95 into particle formation vessel 96. Temperature controlled gas 97
is drawn by
fan 98 in a stream that displaced water vapor from the spray to dry droplets
95 into powder
-30-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
particles 99. Powder particles 99 were transferred to secondary drying chamber
100 where
residual moisture is removed to an acceptable level. The powder particle
product settled
into collection vessel 101 at the bottom of drying chamber 100 for recovery.
[0105] High pressure spraying can be accomplished in a variety of ways known
in
the art, such as by high pressure spraying directly from a high pressure
nozzle, atomizing
the spray with a jet of gasses, and/or high pressure spraying into a cold
fluid. For high
pressure spraying, the suspension or solution can be fed to the nozzle by a
high pressure
pump, such as a HPLC pump, or by application of a high pressure gas on the
holding
container. For atomized spraying, a pressurized gas can be released from
outlets near the
spray outlet orifice to further disrupt and disperse the sprayed droplets. For
spray freeze
drying, the droplets can be sprayed in to a cold (-80°C) gas or liquid
in the particle
formation vessel.
[0106] Drying the droplets with a temperature controlled gas can include
displacement of spray gasses and evaporation of water into a temperature,
humidity, and/or
pressure controlled gas. Fan 98 can draw a stream of gas 97 into the spray of
droplets 95 to
displace spray gasses, such as water vapor, and/or volatile solution
components.
Temperature controller 102 can be a heater or refrigeration system to adjust
the gas
temperature before it enters particle formation vessel 96. The gas can flow
through
humidity controller 103 (a condenser coil or desiccant) to remove moisture. A
vacuum
pump in fluid contact with the collection vessel can remove gasses from the
drying chamber
to speed evaporation from liquid droplets or to lyophilize frozen droplets.
Drying gasses
can be routed through filters, dryers, heat exchangers, activated charcoal
beds, or other
devices to recondition the gas for recycling through the particle formation
and drying
chambers. The process gasses can recirculate in a closed system of conduit or
the system
can be enclosed in an environmental control chamber. Temperature and humidity
sensors in
the recirculating gasses can be adapted to regulate heating, cooling, and/or
humidity control
devices.
[0107] It is understood that the examples and embodiments described herein are
for
illustrative purposes only and that various modifications or changes in light
thereof will be
-31-
CA 02508592 2005-06-02
WO 2004/058156 PCT/US2003/040280
suggested to persons skilled in the art and are to be included within the
spirit and purview of
this application and scope of the appended claims.
[0108] While the foregoing invention has been described in some detail for
purposes
of clarity and understanding, it will be clear to one skilled in the art from
a reading of this
disclosure that various changes in form and detail can be made without
departing from the
true scope of the invention. For example, all the techniques and apparatus
described above
can be used in various combinations without undue experimentation.
[0109] All publications, patents, patent applications, and/or other documents
cited in
this application are incorporated by reference in their entirety for all
purposes to the same
extent as if each individual publication, patent, patent application, and/or
other document
were individually indicated to be incorporated by reference for all purposes.
-32-
